Phenotypes Associated with This Genotype

Genotype
MGI:5695364

• Allelic Composition: Srsf2^tm1.1Oaw/Srsf2⁺; Tg(Mx1-cre)1Cgn/?
• Genetic Background: B6.Cg-Tg(Mx1-cre)1Cgn Srsf2^tm1.1Oaw

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

cellular

abnormal cell cycle ( J:221404 )

• percentage of LSK cells is decreased in G1 and increased in S as compared to controls

increased apoptosis ( J:221404 )

• increase in the proportion of apoptotic hematopoietic stem (LSK) cells

hematopoietic system

abnormal erythropoiesis ( J:221404 )

• erythroid dysplasia

abnormal myelopoiesis ( J:221404 )

• decrease in intermediate myeloid progenitors (pre-MEGE, pre-CFUE)

failure of myelopoiesis ( J:221404 )

• myeloid dysplasia

macrocytic anemia ( J:221404 )

impaired hematopoiesis ( J:221404 )

abnormal erythroid progenitor cell morphology ( J:221404 )

• appearance of nuclear irregularities and cytoplasmic vacuolization and blebbing of erythroid precursors

abnormal neutrophil morphology ( J:221404 )

• appearance of hypolobated and hypogranulated neutrophils

decreased B cell number ( J:221404 )

• decreased numbers of B cells in peripheral blood at all stages beginning at pro-B cell number

increased hematopoietic stem cell number ( J:221404 )

• increase in splenic LSK cells 14 weeks after pIpC injection although splenomegaly is not observed

abnormal hematopoietic system physiology ( J:221404 )

• leukopenia is observed in bone marrow of lethally irradiated recipient mice 18 weeks post-transplantation (pIpC injection 4 weeks after transplantation)

• anemia is observed 18 weeks post-bone marrow transplantation (pIpC injection 4 weeks after transplantation)

• mean corpuscular volume (MCV) is increased in donor bone marrow post-transplantation

• hemoglobin is decreased in donor bone marrow post-transplantation

• increase in total hematopoietic stem cell (LSK) cell number in non-competitive bone marrow transplantation assay 14 weeks after pIpC injection relative to controls

• increase in restricted hematopoietic progenitor cells (LSK, CD48+, CD150+) in bone marrow transplantation assay 14 weeks after pIpC injection relative to controls increase in restricted hematopoietic progenitor cells (LSK, CD48+, CD150+) in bone marrow transplantation assay 14 weeks after pIpC injection relative to controls increase in restricted hematopoietic progenitor cells (LSK, CD48+, CD150+) in bone marrow transplantation assay 14 weeks after pIpC injection relative to controls

• increase in total LSK cell number in bone marrow in competitive bone marrow transplantation assay 14 weeks post-pIpC injection

abnormal hematopoietic stem cell physiology ( J:221404 )

• increase in proportion of apoptotic hematopoietic stem (LSK) cells

• percentage of LSK cells is decreased in G1 and increased in S as compared to controls

immune system

abnormal myelopoiesis ( J:221404 )

• decrease in intermediate myeloid progenitors (pre-MEGE, pre-CFUE)

failure of myelopoiesis ( J:221404 )

• myeloid dysplasia

abnormal neutrophil morphology ( J:221404 )

• appearance of hypolobated and hypogranulated neutrophils

decreased B cell number ( J:221404 )

• decreased numbers of B cells in peripheral blood at all stages beginning at pro-B cell number

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
myelodysplastic syndrome		DOID:0050908	OMIM:614286	J:221404